Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2023-006774 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Mikail Gögenur und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Surgical Science, Department of Surgery, Zealand University Hospital Koge, Koge, Denmark mgog@regionsjaelland.dk. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Influenza Vaccines, Rectal Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Else and Mogens Wedell-Wedellborgs Foundation, Axel Muusfeldts Fond, Aage og Johanne Louis-Hansens Fond.
Abstract (Originalsprache)
Background
In colorectal cancer, the effects of immune checkpoint inhibitors are mostly limited to patients with deficient mismatch repair tumors, characterized by a high grade infiltration of CD8+T cells. Interventions aimed at increasing intratumoral CD8+T-cell infiltration in proficient mismatch repair tumors are lacking.
Methods
We conducted a proof of concept phase 1/2 clinical trial, where patients with non-metastasizing sigmoid or rectal cancer, scheduled for curative intended surgery, were treated with an endoscopic intratumorally administered neoadjuvant influenza vaccine. Blood and tumor samples were collected before the injection and at the time of surgery. The primary outcome was safety of the intervention. Evaluation of pathological tumor regression grade, immunohistochemistry, flow cytometry of blood, tissue bulk transcriptional analyses, and spatial protein profiling of tumor regions were all secondary outcomes.
Results
A total of 10 patients were included in the trial. Median patient age was 70 years (range 54–78), with 30% women. All patients had proficient mismatch repair Union of International Cancer Control stage I–III tumors. No endoscopic safety events occurred, with all patients undergoing curative surgery as scheduled (median 9 days after intervention). Increased CD8+T-cell tumor infiltration was evident after vaccination (median 73 vs 315 cells/mm 2 , p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Surgical Science, Department of Surgery, Zealand University Hospital Koge, Koge, Denmark mgog@regionsjaelland.dk.
- Center for Surgical Science, Department of Surgery, Zealand University Hospital Koge, Koge, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Kobenhavn, Denmark.
- Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Denmark.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.
- Department of Clinical Immunology, Zealand University Hospital Koge, Koege, Denmark.
ORCID-Profile: Mikail Gögenur
Förderung
- Else and Mogens Wedell-Wedellborgs Foundation
- Axel Muusfeldts Fond
- Aage og Johanne Louis-Hansens Fond
Zitieren
APA
Gögenur, M., Balsevicius, L., Bulut, M., Colak, N., Justesen, T. F., Fiehn, A. K., Jensen, M. B., Høst-Rasmussen, K., Cappelen, B., Gaggar, S., Tajik, A., Zahid, J. A., Bennedsen, A. L. B., D'Ondes, T. D. B., Raskov, H., Sækmose, S. G., Hansen, L. B., Salanti, A., Brix, S., & Gögenur, I. (2023). Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006774
Vancouver
Gögenur M, Balsevicius L, Bulut M, Colak N, Justesen TF, Fiehn AK, et al. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006774
BibTeX
@article{Ggenur2023,
author = {Gögenur, Mikail and Balsevicius, Lukas and Bulut, Mustafa and Colak, Nesibe and Justesen, Tobias Freyberg and Fiehn, Anne-Marie Kanstrup and Jensen, Marianne Bøgevang and Høst-Rasmussen, Kathrine and Cappelen, Britt and Gaggar, Shruti and Tajik, Asma and Zahid, Jawad Ahmad and Bennedsen, Astrid Louise Bjørn and D'Ondes, Tommaso Del Buono and Raskov, Hans and Sækmose, Susanne Gjørup and Hansen, Lasse Bremholm and Salanti, Ali and Brix, Susanne and Gögenur, Ismail},
title = {Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2023-006774}
}
EUVIMED